Regeneron Pharmaceuticals Inc. (REGN) News

Regeneron Pharmaceuticals Inc. (REGN): $981.20

16.31 (+1.69%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add REGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#14 of 357

in industry

Filter REGN News Items

REGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

REGN News Highlights

  • For REGN, its 30 day story count is now at 23.
  • Over the past 26 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about REGN are CRS, ASH and CR.

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Regeneron Gains After Eye-Drug Patent Victory Over Viatris

(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be China’s Porsche o

Yahoo | December 27, 2023

7 Undervalued Nasdaq-100 Stocks for Bargain Hunters

Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks.

Josh Enomoto on InvestorPlace | December 22, 2023

Where Will Regeneron Pharmaceuticals Be in 1 Year?

Can the stock continue its market-beating ways?

Yahoo | December 22, 2023

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | December 22, 2023

The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK

Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.

Yahoo | December 19, 2023

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's

Yahoo | December 18, 2023

5 Big Drug Stocks That May Continue to Outperform in 2024

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

Yahoo | December 18, 2023

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

With a price-to-earnings (or "P/E") ratio of 22.9x Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) may be sending...

Yahoo | December 18, 2023

It's Almost 2024: 3 Top Stocks to Buy Before the New Year

You can pick these players up for a great price right now.

Yahoo | December 17, 2023

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!